Mounjaro, Ozempic, Wegovy: never have medications dominated weight loss conversations so much, and never has the gap been wider between what's said on social media and what the data shows. So let's put all the cards on the table. These treatments are unprecedented in their effectiveness: that's true, and we document it with figures to back it up. Weight regain upon discontinuation is massive: that's also true, and almost no one tells you. French reimbursement as of June 2026 is a major advance, reserved for a specific population. And no, there is no "natural Ozempic": not even berberine, an active ingredient with real metabolic benefits that we sell, and that this nickname undermines rather than serves.
We sell dietary supplements. This article nonetheless tells you the whole truth about these medications, including what doesn't work in our favor, because that's our principle: facts first.
Five truths sum up the matter. One: these treatments work at an unprecedented level, -14.9% weight loss in 68 weeks for semaglutide 2.4 mg (Wegovy), up to -20.9% in 72 weeks for tirzepatide (Mounjaro) in pivot trials, versus -2 to -3% under placebo. Two: they don't cure obesity, they control it; one year after stopping, STEP 1 extension participants had regained two-thirds of the weight lost. Three: since June 15, 2026, France reimburses them at 65%, but only for severe obesity (BMI ≥ 40, or ≥ 35 with comorbidity) after failure of nutritional management, with specialized first prescription and reassessment at 4 months. Four: the danger zones are real, online counterfeits, DIY microdosing, cosmetic misuse to lose 3 kilos. Five: no dietary supplement reproduces these effects, and anyone selling you a "natural Ozempic" is lying to you; supplements, berberine included despite its real metabolic benefits, operate in another category, that of modest tools within a constructed dietary framework, and support for weight loss (protein, muscle) regardless of the method.
1. What these treatments really are
GLP-1 is a hormone released by the intestine after a meal: it signals satiety to the brain, slows stomach emptying and stimulates insulin. The treatments everyone is talking about are analogs of this hormone, in a long-acting version injected once a week: semaglutide (marketed as Ozempic for type 2 diabetes, and Wegovy at a higher dose for obesity) and tirzepatide (Mounjaro), which additionally activates a second hormone receptor, GIP, hence its superior effectiveness. In practical terms, patients describe the same thing: the "noise of food" goes quiet, hunger no longer drives the day, portions shrink without a battle.
This mechanism explains everything else in the matter: the effectiveness (appetite is the main lock on weight loss), regain upon stopping (the signal disappears, appetite returns), and digestive effects (slowing a stomach comes at the cost of nausea during the adjustment period).
2. Truth #1: yes, it works, and here are the figures
In 1,961 overweight or obese adults without diabetes, 68 weeks of semaglutide 2.4 mg weekly in addition to lifestyle intervention produced average weight loss of 14.9%, versus 2.4% under placebo; 86% of participants lost at least 5% of their weight, and 50.5% at least 15%, with nausea and diarrhea frequent but generally transient.
Wilding JPH, et al. N Engl J Med 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183
In 2,539 obese adults without diabetes, 72 weeks of weekly tirzepatide produced average weight loss of 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, versus 3.1% under placebo; 57% of participants in the 15 mg group lost at least 20% of their weight, with adverse effects being primarily gastrointestinal, mild to moderate in intensity, occurring mainly during dose escalation.
Jastreboff AM, et al. N Engl J Med 2022;387(3):205-216. DOI: 10.1056/NEJMoa2206038
Let's say it plainly, because the credibility of everything else depends on it: these figures are unprecedented. Weight loss of 15 to 21% of body weight is territory that was only achievable through bariatric surgery; even the best-managed diets typically plateau at 5-10% with frequent regain, and dietary supplements, as we are well positioned to know, count in kilos, not double-digit percentages. For people with obesity and its accompanying comorbidities, these treatments represent a genuine paradigm shift, and the cardiometabolic improvements measured in trials (blood pressure, lipids, blood glucose, even prediabetes regression) confirm this. Two important caveats apply: the trials are funded by the manufacturing laboratories (Novo Nordisk, Eli Lilly), a standard but important-to-know practice, and their participants benefited from lifestyle support that real life doesn't always provide.
3. Truth #2: What happens at discontinuation
One year after stopping weekly semaglutide 2.4 mg and lifestyle intervention, participants followed in the extension had regained an average of 11.6 percentage points of the 17.3% weight lost, approximately two-thirds of the loss, with a return of cardiometabolic variables to baseline values; the authors conclude that these results confirm the chronic nature of obesity and the need for continuous treatment to maintain benefits.
Wilding JPH, et al. Diabetes Obes Metab 2022;24(8):1553-1564. DOI: 10.1111/dom.14725
Here is the data that before-and-after posts on social media never show, and it changes the entire decision. Regain is not a failure of willpower: it is the biology of the mechanism. The drug silences the hunger signal; when stopped, the signal returns, intact, and the body, which defends its previous weight, reclaims the ground. The medical community draws the logical conclusion: obesity is treated like other chronic diseases, over the long term, just as one doesn't stop an antihypertensive because blood pressure has returned to normal under treatment.
Practical consequence for anyone considering these treatments: the real question is not "how much will I lose" but "am I ready for sustained treatment, with its cost, monitoring, and injections". And during treatment, the habits built (protein, activity, sleep) are not merely decorative: they are what will limit the damage if treatment stops, whether by choice or circumstance.
4. Truth #3: Side effects and muscle
The tolerance profile is consistent across trials: digestive effects predominate by far, affecting a significant proportion of patients during progressive dose escalation, and most often diminish over time; nevertheless, they motivate some patients to discontinue treatment. Rare but serious risks (acute pancreatitis, gallbladder disorders) are subject to monitoring, and contraindications are strict: pregnancy and breastfeeding foremost, specific medical history evaluated by the prescriber. Any severe abdominal symptom during treatment requires immediate medical attention.
The point we want to emphasize, because it intersects with our expertise: rapid weight loss is never just fat, a significant portion is lean mass, including muscle. Yet muscle is the metabolic, functional, and aesthetic capital of weight loss: losing it means preparing for regain and a "washed out" appearance. The two solutions are the same as in any weight loss approach, but more imperative here: adequate protein intake (1.6 to 2.2 g/kg/day during weight loss period) and strength training 2 to 3 times per week. No injection exempts you from these fundamentals; it makes them more necessary.
5. Truth #4: France 2026, who, how, how much
This is the weight loss event of the year in France, and it deserves to be described precisely because the media announcement was broader than the official texts. The May 2026 orders organize, from June 15, 2026, the 65% reimbursement (100% for patients with long-term conditions) of Wegovy and Mounjaro, within a deliberately narrow framework: adults with severe obesity, BMI of at least 40, or at least 35 with at least one comorbidity (type 2 diabetes, hypertension, sleep apnea, dyslipidemia, cardiovascular disease), and only after failure of well-conducted nutritional management. The initial prescription is reserved for obesity-specialized structures and physicians; the general practitioner renews but does not initiate. And reimbursement must be earned over time: re-evaluation at 4 months, continued coverage conditional on at least 5% weight loss from baseline.
On the budget side: the maintenance dose of Wegovy shows a public price of approximately €195 per month, now regulated (no more €180 to over €400 variations seen before reimbursement), for a patient out-of-pocket cost of around €50 to €150 per month depending on the molecule and dose, before supplementary health coverage. Outside the criteria, treatment remains entirely the patient's responsibility. The eligible population is estimated between 1 and 2 million people: care priorities have been defined, and not everyone will be served at the same time. The entry point, in all cases: your primary care physician, who will refer you to the specialized pathway.
6. Truth #5: pitfalls to avoid
Online purchasing outside pharmacies. The parallel market is saturated with counterfeit products, under-dosed, over-dosed, or containing anything other than the announced molecule, with documented hospitalizations. An injectable from unknown origin is Russian roulette: the only legitimate channel is prescription + pharmacy.
Microdosing on social media. Taking unstudied dose fractions to "enjoy the effects at lower cost" amounts to self-administering a powerful medication outside any validated framework: unknown benefits, full risks, zero monitoring. If cost or tolerance is an issue, discuss it with your prescriber.
Cosmetic misuse. These treatments are evaluated for obesity, not to lose 3 kilos before an event. Used outside indication, they expose you to the same side effects for a benefit that doesn't justify them, with guaranteed weight regain when you stop. For 5 to 10 kilos, the fundamentals win the benefit-risk ratio match, by far.
7. What about supplements in all this?
We arrive at the section where a supplement website is expected to be on the spot, so let's be completely clear. No dietary supplement reproduces the effect of a GLP-1 agonist. Not apple cider vinegar, not konjac, not berberine, nothing we sell or anything anyone else sells. The berberine case deserves two sentences of fairness: it's a serious active ingredient whose effects on blood sugar and lipids are documented by numerous trials, and it's precisely for this reason that its nickname of "natural Ozempic" manufactured on TikTok does it a disservice, judging it by a promise no capsule in the world can deliver rather than on its own merits. Our Berberine (97% extract) stands by what it is: documented metabolic support, not an injection substitute. Because the orders of magnitude are simply not comparable: the best-documented supplements for weight control produce effects measured in 1 or 2 kilos over 3 months in the best trials, versus 15 to 20% of body weight for these medications. Anyone who blurs this line to sell capsules is lying to you, and this dishonesty harms our entire sector.
What supplements actually do, and it's already useful when stated honestly: modest levers in service of a framework, like the satiety effect of apple cider vinegar or fiber before meals, documented and quantified in our articles with their real limitations; andsupport for weight loss, regardless of method, on critical points: meet protein needs to preserve muscle, ensure micronutrients when appetite (and thus food intake) decreases significantly, which directly affects people on GLP-1, in agreement with their care team. And for those who meet the medical criteria for obesity: the right door is your doctor, not a supplement website, not even ours. Our weight loss collection stays in its proper place: documented actives for calibrated expectations, in a plan that relies first on diet, muscle, and sleep.
Choose the situation that matches yours: the answer appears just below.
With a BMI ≥ 40, or ≥ 35 with comorbidity, and a history of failures despite serious management, you meet the reimbursement criteria as of June 2026. First step: your primary care physician, who documents the nutritional pathway and refers to specialized prescription. Go informed: real efficacy, long-term treatment, protein and muscle from day one.
For 5 to 10 kilos, these medications combine the worst of both worlds: full side effects, full cost (outside criteria, zero reimbursement), and near-guaranteed weight regain upon stopping. The fundamentals win this match without debate: moderate deficit, protein at each meal, strength training, sleep. It's slower, it's on you for life, and your health loses nothing.
Three priorities under treatment: protein 1.6 to 2.2 g/kg/day (reduced appetite causes it to drop without you noticing), strength training 2-3 times per week, and complete transparency with your healthcare team, supplements included if you take any. The quality of your weight loss, and your figure at the end, are decided here. Reassessment at 4 months will value this work precisely.
Any brand selling you a natural equivalent of GLP-1 just failed the simplest honesty test in the industry: no supplement approaches these effects at any dose. Use this signal to sort your sources. Honest supplements announce modest, quantified effects within a framework; others sell dreams with your health as collateral.
This test provides guidance; it does not replace professional medical advice.
Frequently asked questions about Mounjaro, Ozempic and Wegovy
Do Mounjaro and Ozempic really cause weight loss?
Yes, and massively: that's the first truth of this issue. In landmark trials, semaglutide 2.4 mg (the molecule of Ozempic at the Wegovy dose) causes average weight loss of 14.9% over 68 weeks versus 2.4% under placebo, and tirzepatide (Mounjaro) up to 20.9% over 72 weeks at maximum dose, with over half of participants losing at least 20%. No diet, no supplement, no non-surgical method comes close to these numbers. The real question isn't their efficacy: it's for whom, under what conditions, and at what cost.
What happens when you stop these injections?
This is the part media hype forgets: in the STEP 1 trial extension, one year after stopping semaglutide, participants had regained two-thirds of the weight lost, and their cardiometabolic markers had returned to baseline levels. These treatments don't cure obesity: they control it as long as it's taken, like an antihypertensive controls blood pressure. Committing means considering long-term treatment, not a few months of therapy.
Are Mounjaro and Wegovy reimbursed in France?
Yes, since June 15, 2026, at 65% (100% for chronic disease coverage), but within a very strict framework: adults with a BMI of at least 40, or at least 35 with a comorbidity (type 2 diabetes, hypertension, sleep apnea...), after failure of well-conducted nutritional management. First prescription is reserved for specialists, and continued reimbursement is reassessed at 4 months, conditional on at least 5% weight loss. This is not a reimbursed treatment to lose a few kilos before summer.
How much do Wegovy and Mounjaro cost in 2026?
Since June 2026 reimbursement, prices are regulated: the maintenance dose of Wegovy (2.4 mg) lists at approximately €195 per month, reimbursed at 65% for eligible patients, meaning out-of-pocket costs of around €50 to €150 per month depending on the molecule and dose, before supplemental insurance. Outside reimbursement criteria, the full amount remains the patient's responsibility.
What are the side effects of these treatments?
The most common are digestive: nausea, vomiting, diarrhea or constipation, affecting a significant number of patients, especially during gradual dose escalation, and most often transient. Add to this rarer but serious risks monitored by authorities (pancreatitis, gallstones) and strict contraindications, pregnancy foremost. One often-overlooked point: part of the weight lost is muscle, hence the importance of protein and strength training during treatment.
Can you buy Ozempic or Mounjaro online without a prescription?
It's illegal and genuinely dangerous: these injectable medications require a prescription, progressive dose titration, and medical monitoring. The online black market is massively supplied with counterfeits, some of which have caused hospitalizations (under-dosed, over-dosed products, or containing something entirely different, including insulin). No weight loss is worth an injection from an unknown source. The only safe route: medical prescription and pharmacy.
Is Ozempic microdosing a good idea?
No: this social media trend involves taking doses lower than those studied, to cut costs or reduce side effects. The problem is straightforward: the proven benefits from trials correspond to specific doses reached through gradual titration; below that, no one knows what you're getting, and self-medication with an injectable combines all the risks. If cost or tolerability is an issue, the answer is a discussion with your prescriber, not dose manipulation.
Does a natural Ozempic exist?
No, and we say this as a supplement seller: no dietary supplement reproduces the effect of a GLP-1 agonist, not even berberine despite its marketing nickname. Important clarification: berberine is a serious active ingredient, with documented effects on blood sugar and lipids, but in its category—that of metabolic supports—and the "natural Ozempic" nickname does it a disservice by judging it against an unsustainable promise. Pharmaceutical molecules reach concentrations and duration of action that no plant approaches: modest effects in a structured framework on one side, -15 to -20% weight loss on the other. Anyone who blurs this line is misleading you.
Do I need these treatments to lose 5 or 10 kilos?
No: these medications are designed and evaluated for obesity, a chronic disease, not aesthetic weight loss. For 5 to 10 kilos, the benefit-risk ratio heavily favors the fundamentals: moderate caloric deficit, adequate protein, strength training, sleep, with professional support if needed. It's less spectacular on social media, and far healthier for you.
What is the place of dietary supplements in the era of GLP-1s?
An honest and limited place: they neither replace nor mimic these treatments. Their documented roles: support satiety and metabolic comfort within a standard dietary approach (with modest effects, quantified in our articles), and accompany weight loss, medical or otherwise, on critical points like protein intake to preserve muscle. If you are eligible for obesity treatments, the right door is a doctor, not a supplements website—ours included.
- GLP-1
- Intestinal satiety hormone that treatments (semaglutide) mimic in long-acting form; tirzepatide also activates the GIP receptor.
- Semaglutide
- Active molecule in Ozempic (type 2 diabetes) and Wegovy (obesity, 2.4 mg dose).
- Tirzepatide
- Active molecule in Mounjaro, dual GIP/GLP-1 agonist, the more effective of the two in trials.
- ALD
- Long-term condition: status opening 100% coverage for eligible patients.
- Lean mass
- Everything that isn't fat, muscle primarily; part of any rapid weight loss, to be protected through protein and strength training.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725
- Orders of May 23, 2026 listing Wegovy® and Mounjaro® on the reimbursable medications list, Official Journal of May 28, 2026; coverage conditions in effect since June 15, 2026 (Health Insurance, High Authority for Health).
